

December 28, 2024

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra - Kurla Complex,
Bandra (East), Mumbai 400 051

Scrip Code: **500325**

Trading Symbol: **RELIANCE**

Dear Sirs,

Sub: Update to the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investment in Karkinos Healthcare Private Limited

This is further to the disclosure dated December 10, 2024.

In accordance with the approved resolution plan for the resolution of Karkinos Healthcare Private Limited (“**Karkinos**”), Reliance Strategic Business Ventures Limited (“**RSBVL**”), wholly-owned subsidiary of the Company, has on December 27, 2024, subscribed to and has been allotted 1,00,00,000 equity shares of Rs. 10/- each, for cash, aggregating Rs. 10 crore and 36,50,00,000 Optionally Fully Convertible Debentures of Rs. 10/- each, for cash, aggregating Rs. 365 crore of Karkinos.

Further, Karkinos has cancelled the existing outstanding 30,075 equity shares held by the erstwhile shareholders of Karkinos in accordance with the approved resolution plan.

Post allotment of equity shares to RSBVL and cancellation of existing outstanding equity shares as above, Karkinos has become a step down wholly-owned subsidiary of the Company.

Karkinos was incorporated in India on July 24, 2020 and is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.



The turnover of Karkinos for FY 2023, FY 2022, FY 2021 was Rs. 21.911 crore, Rs. 0.918 crore, and Rs. 0.004 crore, respectively. The acquisition of Karkinos will help expand the health services business portfolio of Reliance group.

The resolution plan has been approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, and no further governmental / regulatory approval was required for the above transaction.

The investment does not fall within related party transaction and none of the Company's promoter/promoter group/other group companies have any interest in the above transaction.

The Company has received an intimation from RSBVL on December 27, 2024 at 10:35 p.m.

Thanking you,

Yours faithfully,

For **Reliance Industries Limited**

Savithri Parekh
Company Secretary and
Compliance Officer

Copy to:

Luxembourg Stock Exchange
35A Boulevard Joseph II,
L-1840 Luxembourg

Singapore Exchange Limited
4 Shenton Way, #02-01 SGX Centre 2,
Singapore 068807